Start with how the model actually prices care

A CFO at a 900-employee energy services firm recently asked why their “carve-in” deal with a large insurer produced a $136 PMPM pharmacy cost, even though the PBM’s proposal showed high rebate guarantees. The disconnect came from how the integrated carrier bundled costs inside the medical loss ratio. The HR team assumed discounted pharmacy claims were offsetting medical expenses, but in practice, pharmacy spend was being absorbed into the overall premium math. First rule for 2026: follow the money flow inside any carve-in model before debating rebates or guarantees.

Major insurers like UnitedHealthcare, Cigna, and Aetna still promote carve-in packages that join their PBM arms (OptumRx, Express Scripts, CVS Caremark) directly to the medical plan. They argue integration helps avoid duplicate therapy, track adherence, and align stop-loss triggers. True enough. But cost visibility fades once rebates and dispensing margins roll into medical premium rates instead of a distinct pharmacy ledger. Ask for a line-item reconciliation of pharmacy costs separate from medical, yes, even if it means a custom extract. A transparent model shows PMPM targets for both channels and how rebate and guarantee credits roll through renewals.

Stop assuming integration means insight

Plenty of consultants hear “integrated reporting” and picture a seamless dashboard. In reality, carve-in PBMs often feed through a standard carrier portal that hides pharmacy-level trends. Before buying into combined analytics, test what’s actually delivered. Request sample output that tracks total diabetic cost of care, glucose testing, insulin, inpatient stays together. If all you get are broad averages, that isn’t integration; that’s marketing gloss.

The plans that do it well run quarterly joint reviews of medical and pharmacy use. They spot overlapping spend and act fast: case management outreach, disease program tweaks, formulary alignment. You can do the same even if your PBM and medical carrier are separate, just pipe pharmacy claims into your TPA’s analytics. The label doesn’t matter. Whether the datasets talk to each other does. For up-to-date employer benchmarks on integrated PBM setups, check RxPBM.ai.

Transparency and “all-in” rarely mean the same thing

In 2026, most employers still split medical and pharmacy contracts for one reason, clarity. A carve-in deal often limits audit rights and buries rebate details by folding them into premiums. A 700-life professional services client I worked with saw “rebates” booked as a flat 19% of specialty spend with no proof. When they switched to a stand-alone transparent PBM but kept the same carrier for medical, they received $284,000 in verified rebate payments. Real dollars, not accounting smoke.

Get your PBM amendment to mirror stand-alone audit terms. Clarify drug categories, exclusions, dispensing incentives. Integration muddies where cash actually lands, so finance should confirm how rebates hit specific claims instead of just offsetting the premium base. Otherwise you risk paying twice, once in pharmacy trend, again in the medical loss ratio. A benefits consultant who’s lived through carve-in audits can map it, comparing total paid data across models until the numbers line up.

If you want balance, here’s what it looks like

A 500-employee manufacturer in Ohio took an 8.5% renewal hike on a combined medical-pharmacy carve-in. Pharmacy trend alone: $124 PMPM, driven by semaglutide and adalimumab categories. They pivoted to a hybrid, keeping the carrier for medical stop-loss and disease management but adding a transparent PBM contract directly. By mid-2025, pharmacy PMPM sat at $109. Integrated analytics flagged 29 diabetics driving 18% of total medical spend, and management finally had the data to act.

That blend worked because the PBM pushed daily claims feeds into the insurer’s population health platform. Cross-channel review became routine. The employer kept audit rights, could change the formulary midyear, and owned every data line, down to the NDC code. That’s the quiet power here. Define data ownership, not just data sharing. Once it’s yours, everything else gets easier.

What to do before renewal hits

Before your next cycle, pull together your PBM manager, carrier rep, and finance lead. Goal: trace every pharmacy dollar from claim to premium. Compare the insurer’s integrated PMPM to your raw PBM claim totals. You’ll almost always uncover hidden admin layers or missing rebate credits. Quantify that gap, then decide if the carve-in still earns its keep or if unbundling makes more sense. When you need to test your numbers against market drug-level pricing, go straight to RxInfo.ai.

Look, every employer says they want integration until they realize how hard it is to see where the money actually goes. Once you’ve mapped it, you’ll know. Or at least you’ll stop guessing.